slot machine attendant Donald Trump criticizes Kate Hobbs’ border policiesFootball teams across the Northern Section are preparing for a rainy Friday night of playoff games. For many teams Friday will be the second round of NSCIF playoffs. For teams like Pleasant Valley and Foothill in D-II, it will be their first game of section playoffs after first-round byes. For many others it will be second round semifinal matchups, and in Division IV the matchup between Winters and East Nicolaus is the division’s Northern Section championship. That game has been moved to Saturday at 1 p.m.; Northern Section commissioner Scott Johnson confirmed there was a mutual agreement between the two programs, who felt with a section championship on the line, they would get better break in weather with Winters’ home field being on grass. Johnson added that five of the seven games scheduled for this weekend will be played on grass fields — Pleasant Valley and Foothill’s fields in Division II the only exceptions — and that all schools are communicating with everyone involved. Johnson said teams could opt to move the games as late as Friday morning to a later date or change of time, as long as enough time is given to all involved including media, officials, MaxPreps, section officials and others. As of Thursday at 12:30 p.m., the only other change that has been made is that in Division III: No. 5 Gridley (8-3) playing at No. 1 Lassen (8-3) has been moved from 7 p.m. to 6 p.m. “We’re trying to stay status quo,” Johnson said. Kicking off in D-II, No. 1 Pleasant Valley (7-3) hosts No. 4 Enterprise (8-3) at 7 p.m. at Asgard Yard in Chico. The Vikings received a first-round bye while the Hornets came from behind to defeat Shasta 26-20 in the quarterfinals. The Hornets outscored Shasta 20-0 in the second half to advance. In the regular season Enterprise and PV faced off on Nov. 1 in another rainy game, and the Vikings defeated the Hornets 38-17. PV threw for three touchdowns and ran for two in that game. Lucas Benson had 19 carries for 156 yards and one TD in addition to a 19-yard TD pass, and QB Joseph Garcia threw for 149 yards and two TDs. Enterprise QB JJ Johnson threw for 226 yards and two TDs, was intercepted once, but the Vikings limited the dual-threat quarterback to just four carries for 22 yards. On the bottom half of the D-II bracket, No. 2 Foothill (7-3) hosts No. 3 Red Bluff (9-2) at 7 p.m. in Palo Cedro. This game very well could have been in Red Bluff had the coach’s committee not made a mistake at the seeding meeting. The two teams enter having different momentum shifts. After Foothill began its season having won six of its first seven, the Cougars lost two of three to close out their season. Meanwhile Red Bluff, which lost 29-26 at home against Foothill on Oct. 18, has won four straight since the loss. During the regular season matchup the Cougars and Spartans were tied at 14-14 at halftime, and after a scoreless third quarter the Cougars scored in the final two minutes and sealed the win with a 2-point conversion. Red Bluff defeated No. 6 Las Plumas 42-0 in the opening round, while Foothill’s last game played before the bye week was a 32-13 loss to Enterprise on Nov. 8. Kicking off at 7 p.m., No. 2 Orland (9-2) and No. 6 Corning (5-6) face off for a second time this season in Orland. The first game between the Trojans and Cardinals was played in the rain on Orland’s grass field, and the forecast shows this will likely be the case once again. The Trojans defeated the Cardinals 34-14 on Nov. 1. After that game Corning coach John Studer said the conditions favor Orland’s downhill run game, whereas Corning likes to get to the edge more and cut, which can be hard on muddy field conditions. Corning upset No. 3 Yreka 24-20 last week, after being down 20-3 at one point. Orland is coming off a 42-6 win against No. 7 Pierce, in which quarterback Luke Schager set a new single-game rushing record for Orland football with 417 yards and four TDs. The Trojans’ defense shut out the Bears, with their lone score coming on a fumble returned for a TD. The D-III section championship will be held at 7 p.m. Nov. 30 at the higher seed’s home field. No. 1 Winters (11-0) looks to stay undefeated when it hosts No. 2 East Nicolaus (7-4) for the NSCIF D-IV championship Saturday. Winters defeated No. 4 Hamilton 48-0 in the first round, while East Nicolaus defeated No. 3 Durham 40-28. The Warriors have seven of their 11 games via shutout, including defeating East Nicolaus 48-0 on Oct. 18 in Winters, and outscored their opponents 429-43. East Nicolaus has won three straight and outscored its opponents 312-235. While the D-II and D-III section championship games are held Nov. 30, the D-V section championship game is held the day before Thanksgiving on Nov. 27. The biggest implication this has for Friday’s games is that the two D-V semifinals must go on as scheduled (with the exception of lightning cancelling) to give teams time to prepare, whereas in other divisions games could be pushed towards future dates. No. 4 Los Molinos (6-5) hosts No. 8 Weed (5-6) at 7 p.m. in Los Molinos. Weed upset No. 1 Biggs in the quarterfinals 16-14, while Los Molinos defeated No. 5 Modoc 68-37. The Cougars and Bulldogs did not face off in the regular season. In the bottom half of the bracket, No. 2 Maxwell (10-1) hosts No. 6 Redding Christian (6-5) at 7 p.m. in Maxwell. Redding Christian upset No. 3 Etna 29-0, while Maxwell defeated No. 7 Fall River 41-30. Maxwell defeated Redding Christian 44-14 in both teams’ third game of the regular season on Sept. 13 in Redding. The winners of both games will face off at 7 p.m. Nov. 27 at the higher seed’s home field.

Bangladesh to face Internet disruption on Dec. 2

Is this finally the end for Bashar al-Assad? Islamist rebels seize control of Aleppo and punch through into Hama city amid claims Syria's monster dictator has now 'fled with his family to Russia' - as his embattled regime looks on the brink of collapseOne of my top shows of 2024 actually premiered in 2021. That’s because it took a couple of years for the Australian series “The Newsreader” to make its way Stateside. Alas, it was only legal to stream in the U.S. for a handful of weeks in September and then — pffft! — it was gone before most people had even heard of it. Well, I have great news. The show will be available once again, this time via Sundance Now (accessible through the AMC+ streaming platform), which has licensed the first season. Premiering Dec. 19, it stars Anna Torv (“Fringe”) and Sam Reid (“Interview with the Vampire”) as TV reporters in Melbourne, circa 1986. At the outset, Reid’s character exudes big loser energy, which is such an amusing contrast to his work as Lestat. The show is unexpectedly funny and terrifically Machiavellian in its portrayal of small-time office politics, and I’m thrilled audiences in the U.S. will get another shot at watching it. Overall, 2024 offered a modestly better lineup than usual, but I’m not sure it felt that way. Too often the good stuff got drowned out by Hollywood’s pointless and endless pursuit of rebooting intellectual property (no thank you, Apple’s “Presumed Innocent” ) and tendency to stretch a perfectly fine two-hour movie premise into a saggy multi-part series (“Presumed Innocent” again!). There were plenty of shows I liked that didn’t make this year’s list, including ABC’s “Abbott Elementary” and CBS’ “Ghosts” (it’s heartening to see the network sitcom format still thriving in the streaming era), as well as Netflix’s “A Man on the Inside” (Ted Danson’s charisma selling an unlikely premise) and Hulu’s “Interior Chinatown” (a high-concept parody of racial stereotypes and cop show tropes, even if it couldn’t sustain the idea over 10 episodes). Maybe it just felt like we were having more fun this year, with Netflix’s “The Perfect Couple” (Nicole Kidman leading a traditional manor house mystery reinterpreted with an American sensibility) and Hulu’s “Rivals” (the horniest show of 2024, delivered with a wink in the English countryside). I liked what I saw of Showtime’s espionage thriller “The Agency” (although the bulk of episodes were unavailable as of this writing). The deluge of remakes tends to make me cringe, but this year also saw a redo of Patricia Highsmith’s “The Talented Mr. Ripley” on Netflix that was far classier than most of what’s available on the streamer. Starring Andrew Scott, I found it cool to the touch, but the imagery stayed with me. Shot in black and white, it has an indelible visual language courtesy of director of photography Robert Elswit, whether capturing a crisp white business card against the worn grain wood of a bar top, or winding stairways that alternately suggest a yawning void or a trap. As always, if you missed any of these shows when they originally premiered — the aforementioned titles or the Top 10 listed below — they are all available to stream. Top 10 streaming and TV shows of 2024, in alphabetical order: “Couples Therapy” (Showtime) The least cynical reality show on television remains as absorbing as ever in Season 4, thanks to the probing questions and insights from the show’s resident therapist, Dr. Orna Guralnik. Everything is so charged. And yet the show has a soothing effect, predicated on the idea that human behavior (and misery) isn’t mysterious or unchangeable. There’s something so optimistic in that outlook. Whether or not you relate to the people featured on “Couples Therapy” — or even like them as individuals — doesn’t matter as much as Guralnik’s reassuring presence. “Diarra From Detroit” (BET+) Created by and starring Diarra Kilpatrick, the eight-episode series defies categorization in all the right ways. Part missing-person mystery, part comedy about a school teacher coming to grips with her impending divorce, and part drama about long-buried secrets, it has tremendous style right from the start — sardonic, knowing and self-deprecating. The answers to the central mystery may not pack a satisfying punch by the end, but the road there is as entertaining and absorbing as they come. We need more shows like this. “English Teacher” (FX) A comedy created by and starring Brian Jordan Alvarez (of the antic YouTube series “The Gay and Wondrous Life of Caleb Gallo”), the show has a sensibility all its own, despite a handful of misinformed people on social media calling it a ripoff of “Abbott Elementary.” There’s room enough in the TV landscape for more than one sitcom with a school setting and “English Teacher” has a wonderfully gimlet-eyed point of view of modern high school life. I’m amused that so much of its musical score is Gen-X coded, because that neither applies to Alvarez (a millennial) nor the fictional students he teaches. So why does the show feature everything from Laura Branigan’s “Gloria” to Exposé’s “Point of No Return”? The ’80s were awash in teen stories and maybe the show is using music from that era to invoke all those tropes in order to better subvert them. It’s a compelling idea! It’s streaming on Hulu and worth checking out if you haven’t already. “Fifteen-Love” (Sundance Now) A one-time tennis phenom accuses her former coach of coercing her into a sexual relationship in this British thriller. The intimacy between a coach and athlete often goes unexplored, in real-life or fictional contexts and that’s what the show interrogates: When does it go over the line? It’s smart, endlessly watchable and the kind of series that would likely find a larger audience were it available on a more popular streamer. “Hacks” (Max) There’s real tenderness in this show. Real cruelty, too. It’s a potent combination and the show’s third and strongest season won it an Emmy for best comedy. Jean Smart’s aging comic still looking for industry validation and Hannah Einbinder’s needy Gen-Z writer are trapped in an endless cycle of building trust that inevitably gives way to betrayal. Hollywood in a nutshell! “Hacks” is doing variations on this theme every season, but doing it in interesting ways. Nobody self-sabotages their way to success like these two. “Interview with the Vampire” (AMC) I was skeptical about the show when it premiered in 2022 . Vampire stories don’t interest me. And the 1994 movie adaptation starring Tom Cruise and Brad Pitt wasn’t a persuasive argument to the contrary. But great television is great television and nothing at the moment is better than this show. It was ignored by Emmy voters in its initial outing but let’s hope Season 2 gets the recognition it deserves. Under showrunner Rolin Jones, the adaptation of Anne Rice’s novels is richly written, thrillingly inhabited by its cast and so effortlessly funny with a framing device — the interview of the title — that is thick with intrigue and sly comedy. I wouldn’t categorize the series as horror. It’s not scary. But it is tonally self-assured and richly made, rarely focused on the hunt for dinner but on something far more interesting: The melodrama of vampire existence, with its combination of boredom and lust and tragedy and zingers. Already renewed for Season 3, it has an incredible cast (a thrilling late-career boost for Eric Bogosian) and is well worth catching up with if you haven’t already. “Nobody Wants This” (Netflix) It’s been too long since the pleasures of banter fueled a romantic comedy in the spirit of “When Harry Met Sally.” But it’s all over the place in “Nobody Wants This,” one of the best shows on Netflix in recent memory. Renewed for a second season, it stars Kristen Bell as a humorously caustic podcaster and Adam Brody as the cute and emotionally intelligent rabbi she falls for. On the downside, the show has some terrible notions about Jewish women that play into controlling and emasculating stereotypes. You hate to see it in such an otherwise sparkling comedy, because overall Bell and Brody have an easy touch that gives the comedy real buoyancy. “Nolly” (PBS Masterpiece) I suspect few people saw this three-part series on PBS Masterpiece, but it features a terrific performance by Helena Bonham Carter playing the real-life, longtime British soap star Noele “Nolly” Gordon, who was unceremoniously sacked in 1981. She’s the kind of larger-than-life showbiz figure who is a bit ridiculous, a bit imperious, but also so much fun. The final stretch of her career is brought to life by Carter and this homage — to both the soap she starred in and the way she carried it on her back — is from Russell T. Davies (best known for the “Doctor Who” revival). For U.S. viewers unfamiliar with the show or Gordon, Carter’s performance has the benefit of not competing with a memory as it reanimates a slice of British pop culture history from the analog era. “Shōgun” (FX) The year is 1600 and a stubborn British seaman piloting a Dutch ship washes ashore in Japan. That’s our entry point to this gorgeously shot story of power games and political maneuvering among feudal enemies. Adapted from James Clavell’s 1975 novel by the married team of Rachel Kondo and Justin Marks, it is filled with Emmy-winning performances (for Anna Sawai and Hiroyuki Sanada; the series itself also won best drama) and unlike something like HBO’s far clunkier “House of the Dragon,” which tackles similar themes, this feels like the rare show created by, and for, adults. “Slow Horses” (Apple TV+) The misfits and losers of Britain’s MI5 counterintelligence agency — collectively known as the slow horses, a sneering nickname that speaks to their perceived uselessness — remain as restless as ever in this adaptation of Mick Herron’s Slough House spy novels. As a series, “Slow Horses” doesn’t offer tightly plotted clockwork spy stories; think too deeply about any of the details and the whole thing threatens to fall apart. But on a scene-by-scene basis, the writing is a winning combination of wry and tension-filled, and the cumulative effect is wonderfully entertaining. Spies have to deal with petty office politics like everyone else! It’s also one of the few shows that has avoided the dreaded one- or two-year delay between seasons, which has become standard on streaming. Instead, it provides the kind of reliability — of its characters but also its storytelling intent — that has become increasingly rare. Nina Metz is a Tribune critic.

Top Arab diplomats visited the Syrian capital, Damascus, on Monday, the latest in a string of diplomatic overtures by the international community as Syria emerges from years of isolation under President Bashar Assad. The visits by ministers from Jordan and Qatar, just two weeks after Assad’s fall, suggest that Arab nations are eager for better relations with a country that had been a pariah and a source of instability in the region. Syria’s New Leader Holds Talks With Jordan’s Leadership Syria’s new leader, Ahmad al-Sharaa, held “extensive talks” with Jordan’s foreign minister, Ayman Safadi, in Damascus on Monday, according to a statement from the Jordanian Foreign Ministry. Hours later, Qatar’s minister of state for foreign affairs, Mohammed al-Khulaifi, arrived in Syria and met with its new leadership, according to the Qatari Foreign Ministry. They were among the first high-ranking Arab diplomats to visit Syria since Assad was toppled two weeks ago by the rebel coalition led by al-Sharaa. Top Arab diplomats vowed at a meeting in Jordan this month to “support a peaceful transition process” in Syria. Most Arab nations cut ties with Assad’s government because of his ruthless crackdown on pro-democracy protesters in 2011 during the Arab Spring, which ignited a civil war. But after years of financing anti-Assad militias, several of Assad’s detractors had reversed their stance in recent years, hoping that increased engagement might bring more stability to the region. Last year, the Saudi government in Riyadh invited Assad to the Arab League summit, more than a decade after the league suspended Syria’s membership. But the strategy didn’t pay off, said Julien Barnes-Dacey, Middle East and North Africa program director at the European Council on Foreign Relations. And Assad continued with his heavy-handed tactics. Now, Arab nations are jumping at the chance to start again with new leadership in Syria. “The Arab states see more opportunity now than they did after a year of engagement with Assad that delivered absolutely nothing,” Barnes-Dacey said. Initially there was trepidation given al-Sharaa’s former links to al-Qaida, which is as much a destabilizing factor in the Arab world as it is in the West, Barnes-Dacey said. But al-Sharaa’s repeated pronouncements that his government would be pragmatic, inclusive and respectful of the country’s many religious and ethnic groups have been well received. “Regional states are going to be happy to jump on that,” he said. Shifts in Regional Alliances The influx of Arab delegations reflects the potential for a profound shift in regional alliances, said Paul Salem, vice president for international engagement at the Middle East Institute in Washington. Even though like most Arab nations, Syria is a majority Sunni Muslim country, the Assad regime long played a key role in supporting the regional influence of Iran, which is largely Shiite. Arab states see an opportunity to change that dynamic. “Arab countries have been trying to get Syria back into the Arab fold for the last 45 years, since the Iran-Iraq war,” Salem said. It is not surprising, he added, that Qatar is taking the lead. Qatar was one of the few Arab countries that refused to reconcile with Assad, so the visit by al-Khulaifi, one of the country’s top-ranking diplomats, was a strong signal of support for the new government. In a news conference after their meeting, al-Khulaifi said that “Syria and its people need support during this crucial phase.” Al-Sharaa highlighted Qatar’s continued assistance for the Syrian people throughout the war, and thanked Qatar for what he described as its readiness to invest in Syria’s energy sector, ports and airports. The Qatari delegation was accompanied by a technical team from Qatar Airways that planned to assess whether the international airport in Damascus was ready to restart operations after it was shut down amid the rebel offensive, according to the Foreign Ministry. Safadi said in remarks after his meeting with al-Sharaa that Jordan’s goal was to “support and assist the Syrian people.” But he also brought up issues of direct concern to Jordan, including the presence of nearly 620,000 registered Syrian refugees in his country, emphasizing that their return must be “voluntary and safe.” Safadi also brought up issues of terrorism, arms smuggling and drug trafficking, “which we in Jordan have suffered from.” United Arab Emirates Speaks With New Syrian Leadership The foreign minister of the United Arab Emirates, Sheikh Abdullah bin Zayed Al Nahyan, spoke with Asaad Hassan al-Shibani, Syria’s newly appointed foreign minister. In the call, bin Zayed stressed his country’s “supportive stance” for a “comprehensive and inclusive transitional phase.” The UAE has long been suspicious of the rebel movement’s Islamist bent, said Barnes-Dacey, and was the first among Arab nations to reestablish ties with the Assad government, in 2018. On Sunday al-Sharaa met with the Turkish foreign minister, Hakan Fidan, and also met a prominent Lebanese Druze leader, Walid Jumblatt. Like his visitors Monday, the Turkish and Lebanese representatives had their list of needs, couched in offers of support. Turkey, host to 3.6 million Syrian refugees, also wants to see a return to stability so that they can eventually go home. But it is also seeking to build a Syria more closely aligned with its regional interests. Many of the rebel groups that helped push Assad out of power were financed by Turkey, and while al-Sharaa’s group was not, Turkey will still seek to use their presence to push for greater influence, Barnes-Dacey said. As a Lebanese politician as well as the leader of the Druze religious minority, which has about a million members scattered across Syria, Lebanon, Israel and Jordan, Jumblatt wasn’t seeking influence as much as reassurances. The Assad regime, which was founded by Assad’s father, Hafez Assad in 1971, had a long history of interfering in Lebanese politics, and it was implicated in the assassination of Jumblatt’s father, as well as the killings of former Prime Minister Rafic Hariri and several other prominent Lebanese politicians over the past 50 years. In his meeting with the Lebanese delegation, al-Sharaa acknowledged that Syria under the Assads had long been a “source of fear and anxiety” for Lebanon, and he vowed to end his country’s “negative interference.” — This article originally appeared in . By Aryn Baker and Euan Ward/Daniel Berehulak c. 2024 The New York Times Company

After upset win, Penn State out to extend Rutgers' woesBlake Lively, Ryan Reynolds' Kids "Traumatized" By Alleged CampaignNuScale Power Announces Appointment of Diana J. Walters to Board of Directors

COLUMBIA, Mo. (AP) — Arkansas defensive end Landon Jackson was carted off the field and taken to a hospital with a neck injury late in the first half of Saturday's game at No. 24 Missouri. Jackson appeared to injure his neck while trying to tackle Missouri running back Jamal Roberts. Medical personnel tended to Jackson for approximately 10 minutes before he was placed on a backboard and driven to a waiting ambulance. Jackson gave a thumbs-up sign as he was carted off the snow-covered field. Arkansas athletic director Hunter Yurachek said Jackson had movement in his arms and legs but was experiencing pain in his neck. He said Jackson was taken to the hospital as a precaution. Jackson leads the Razorbacks with 9 1/2 tackles for loss and 6 1/2 sacks, and is considered a potential first-round pick in next year's NFL draft. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football

Blue Owl Capital: 9.7% Yield And 127% Dividend Coverage Make It A BuyPeter Dutton has been accused of blocking a show of political unity and stopping a Liberal senator from reading out the local Labor MP’s statement in the wake of the Melbourne synagogue firebombing. Macnamara MP Josh Burns, who had physically lost his voice on Friday, appeared alongside Coalition foreign affairs spokesman James Paterson and a number of state and federal Liberals outside the Adass Israel synagogue on Friday, after the early morning terror attack. Mr Burns claims Senator Paterson had agreed to read out his words, but Opposition Leader Peter Dutton intervened. “James agreed to read out a statement from me, because I thought it was really important there be a united front,” Mr Burns told ABC RN Breakfast on Tuesday. “Unfortunately, right before we got on, Peter Dutton intervened and told James that he wasn’t allowed to read out the statement. “Peter Dutton told James that he wasn’t allowed to read out my words. I wanted to stand out with James and present a united front on this, and Peter Dutton decided that it was more important to play partisan games than to allow my words that I physically couldn’t speak to be read out.” Mr Burns’ statement, which labelled the attack a “disgrace and extremely dangerous” was instead ready by the Executive Council of Australian Jewry president Daniel Aghion. Mr Burns on Tuesday said despite having no voice, “I wanted to make sure that my community knew that I was there, and that we do this in a bipartisan way”. “I wanted to show unity,” he told ABC News. “If we’re going to play those sorts of politics, I don’t think it’s in our best interests. I compare that with community leaders who have been working with people avross the Parliament regardless of their political stripes. “I’ll stand up with anyone at this moment... I don’t care. I care about my community.” In response to Mr Burns’ claims, Senator Paterson on Tuesday said that he felt “very sorry that Josh Burns and his community have been abandoned by the Labor Party in the wake of this terror attack”. “But it is not the role of a Liberal frontbencher to act as a spokesman for a Labor MP,” Senator Paterson said. “One of the many senior Albanese Government ministers should have been there to speak if Josh was not able to.” The early morning attack was on Monday deemed a likely terror incident. Prime Minister Anthony Albanese has also stood up a federal taskforce, led by the Australian Federal Police and ASIO, to combat anti-Semitism. The Coalition have slammed Mr Albanese for not yet having visited the synagogue site - although he is expected to do so this week, potentially on Tuesday. Senator Paterson earlier told the ABC Melbourne’s Jewish community were “disappointed” in the lack of leadership shown by the entire Labor cabinet. “I think it is strange that we’re now five days on from this happening and the Prime Minister still hasn’t attended and nor has any senior national security minister of the government, not the Home Affairs Minister (Tony Burke), not the Attorney-General (Mark Dreyfus),” he said. The latest development in the politicking came after one of the world’s most prominent Jewish human rights organisations prepares to issue a global warning against travel to Australia. The Simon Wiesenthal Centre in the United States reached out to community members through social media in the wake of the Ripponlea attack to say: “Arsonists burned a Melbourne synagogue, built by Holocaust survivors, injuring Jews and damaging sacred religious items”. “Jews were trapped inside a Sydney synagogue by Hamas supporters, and a Jewish bakery in Melbourne was targeted by antisemites,” the organisation said, referencing other incidents that occured within days of the Melbourne terror attack. “These attacks coincide with Australia’s vote at the UN supporting an anti-Israel resolution calling for Israel to leave parts of Jerusalem and the West Bank — an action that would leave the Jewish state with indefensible borders.”

A Dutch court weighs a lawsuit against arms sales to Israel( MENAFN - GlobeNewsWire - Nasdaq) NEW YORK, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against ASP Isotopes, Inc (“ASP Isotopes” or the“Company”) (NASDAQ: ASPI) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired ASP Isotopes securities between October 30, 2024 and November 26, 2024, both dates inclusive (the“Class Period”). Investors have until February 3, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. On November 26, 2024, Fuzzy Panda Research published a report which alleged that ASP Isotopes is“using old, disregarded laser enrichment technology to masquerade as a new, cutting-edge Uranium enrichment.” The report quoted a former employee of Klydon (the company ASP Isotopes purchased its“proprietary” technology from) as stating scientists“did not think it would work on Uranium.” The report revealed a series of experts interviewed stated the Company's reported cost estimates and timeline for building its HALEU uranium facilities was misleading to the point of being“delusional.” The report further alleged the Company had significantly overstated the significance of its agreement with TerraPower, which was only a“non-binding” memorandum of understanding entered into to“put pressure on [TerraPower's] real suppliers.” The report quoted a former TerraPower executives as stating that ASP Isotopes was“missing the manufacturing; They are missing the processes as well; They still have to develop the HALEU...the most important part.” Finally, the report revealed that the Company's subsidiary, Quantum Leap Energy, which operates its nuclear fuels segment and to which the Company assigned the TerraPower memoranda of understanding, was completely absent from its registered South African address. The report revealed there were“zero signs” of their presence and“security guards and neighboring business about them all told us they had never heard of the companies.” On this news, the Company's stock price fell $1.80 or 23.53%, to close at $5.85 per share on November 26, 2024, on unusually heavy trading volume. The stock continued to fall on the subsequent trading date, falling $0.83 or 14.19%, to close at $5.02 per share on November 27, 2024, on unusually heavy trading volume. The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) the Company overstated the potential effectiveness of its enrichment technology; (2) the Company overstated the development potential of its high assay low-enriched uranium facility; (3) the Company overstated the Company's nuclear fuels operating segment results; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. If you purchased or otherwise acquired ASP Isotopes shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at ... , telephone at (212) 355-4648, or by filling out this contact form . There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Marion Passmore, Esq. (212) 355-4648 ... MENAFN26122024004107003653ID1109033704 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.Explore Beyond What You Can See! Distant Horizons Setting Revolutionizes GamingTrump’s cameo in ‘Home Alone 2’ tops long list of president-elect’s acting roles

Adele has said she will miss her residency shows “terribly” but needs to “move on” after playing her 100th and final show in Las Vegas on Saturday night. The British singer-songwriter, 36, launched Weekends With Adele, located at The Colosseum theatre in Caesars Palace in November 2022. In July, she announced she would be taking a “big break” from music after her run of of sell-out shows at the venue, which seats around 4,000 people. In a social media post on Monday, she said: “Well what an adventure! Las Vegas you’ve been so good to me. “This residency went on to mirror what 30 was about, lost and broken to healed and thriving! “Seems so fitting in the end. The only thing left to do in this case is move on.” The Easy On Me star made a return to the spotlight in 2021 when she released her fourth album, 30. Adele said: “These 100 shows have been so easy to love. “They were all completely different because I got to really be with every single person in the room every night. “I’ve loved every single second of it and I am so proud of it! I will miss it terribly, and I will miss you all terribly too. Thank you! Thank you! Thank you! See you next time.” Videos posted online from her concert on Saturday show the singer getting tearful as she bid farewell to Vegas. “It’s been wonderful and I will miss it terribly and I will miss you terribly,” she said. “I don’t know when I next want to perform again.” The singer, full name Adele Adkins, shared an emotional embrace with Celine Dion after she spotted the music artist in the audience during her Las Vegas show last month. In August, Adele played shows in a purpose-built outdoor arena in Munich, with capacity for 80,000 people per night, and told fans on the last night that they would not be seeing her for a “long time”.Cardinals' sudden 3-game tailspin has turned their once solid playoff hopes into a long shotThe main opposition Democratic Party of Korea chief Lee Jae-myung, center, joins party lawmakers and supporters to stage a rally in central Seoul calling for the government to accept a special counsel bill against first lady Kim Keon Hee, Nov. 30. Yonhap The main opposition Democratic Party of Korea (DPK) and its supporters held a massive rally in central Seoul on Saturday, lashing out at the Yoon Suk Yeol government for what they called the mishandling of state affairs and demanding a special counsel probe into first lady Kim Keon Hee. DPK leader Lee Jae-myung and around 100,000 party members and supporters — a count claimed by the party — gathered near Gwanghwamun Square and staged a rally, according to police and party officials. The protest was the fifth of its kind. The participants called on Yoon to accept a bill for a special counsel probe into Kim for her alleged involvement in a stock manipulation scheme, the alleged interference in election nominations through a broker and the acceptance of a luxury bag, among other things. Yoon on Tuesday vetoed the bill, the third time he has rejected the DPK-led bill. "Judging Yoon Suk Yeol and punishing Kim Keon Hee ... are all a battle for democracy," Rep. Kim Min-seok told supporters. (Yonhap)

All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach 6-Month Follow-up Remains in DORIS Clinical Remission and Free of All Immunosuppressive Therapies Company Plans to Initiate Dose Expansion at First Dose Level of 360M Cells SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today presented new clinical and translational data from the Company’s FT819 Phase 1 Autoimmunity study for moderate-to-severe systemic lupus erythematosus (SLE) at the American Society of Hematology (ASH) Annual Meeting being held in San Diego, CA. The first three study patients, each of whom presented with active lupus nephritis (LN) despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning followed by a single dose of FT819 at 360 million cells. There were no dose-limiting toxicities (DLTs), no events of any grade of cytokine release syndrome (CRS), immune effector-cell associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GvHD), and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. FT819 is the Company’s off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking. “We continue to be very pleased with early clinical observations of fludarabine-free conditioning and FT819 off-the-shelf, CAR T-cell therapy in patients with moderate-to-severe SLE. The remarkable experience of the first patient treated in April is ongoing, as the patient remains on-study in drug-free clinical remission. In addition, the initial clinical and translational data from the two additional patients treated at the first dose level continue to support the potential for disease transformation,” said Bob Valamehr, President of Research and Development of Fate Therapeutics. “We are now initiating dose expansion at this first dose level to accelerate development, and are also escalating dose based on the favorable safety profile observed. In addition, I am pleased to announce that the first patient has now been treated with FT819 as an add-on to maintenance therapy without conditioning chemotherapy. We believe our therapeutic approach is highly-differentiated and has the potential to transform disease outcomes without requiring patient apheresis, discontinuation of maintenance therapy, intense conditioning chemotherapy, and extended hospitalization.” FT819 Phase 1 Autoimmunity Study The ongoing multi-center, Phase 1 clinical trial for patients with moderate-to-severe SLE is designed to evaluate the safety, pharmacokinetics, and anti-B cell activity of FT819 (NCT06308978). The first three patients, all of whom presented with active LN despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning consisting of either cyclophosphamide alone or bendamustine alone, followed by a single dose of FT819 at 360 million cells. In all three patients, FT819 was detected in the peripheral blood and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. All three patients remain on-study, and there have been no DLTs and no events of any grade of CRS, ICANS, or GvHD. Based on these clinical observations, the Company is initiating dose expansion in up to 10 patients at this first dose level, and is also escalating dose to 720 million cells. The Company’s FT819 Phase 1 Autoimmunity study also includes a second treatment arm to assess the safety, pharmacokinetics, and anti-B cell activity of a single dose of FT819 as an add-on to maintenance therapy without conditioning chemotherapy in patients with SLE. The first patient has now been treated in this second arm, which is being conducted in parallel with the study’s conditioning arm. FT819 Patient 1 Case Study The first patient treated in the Phase 1 Autoimmunity study presented with active LN and severe disease, which was marked by renal BILAG A (British Isles Lupus Assessment Group) disease activity score based on biopsy, SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index) score of 20, FACIT-Fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue) score of 33 (range 0-52, where a score of 52 indicates no fatigue) and PGA (Physician Global Assessment) score of 2.5 (where a score of 3 indicates most severe activity). Following administration of fludarabine-free conditioning and treatment with a single dose of FT819 at 360 million cells, the patient was discharged from the hospital without notable adverse events (AEs) after a protocol-required three-day stay. Rapid elimination of CD19+ B cells in the periphery was observed following treatment, and B-cell recovery by Month 3 was predominantly comprised of naïve, non-class switched B cells with near-complete elimination of switched memory B cells and deep depletion of plasmablasts, indicative of an immune reset. The patient reported that her debilitating fatigue had entirely resolved without further treatment, and treatment with methylprednisolone was discontinued at Month 3. The patient achieved DORIS (definition of remission in SLE) clinical remission, including with resolution of arthritis and active urinary sediment and with a substantial reduction in proteinuria, as of Month 6 follow-up. The patient continues on-study, in DORIS clinical remission, and remains free of all immunosuppressive therapy. iPSC-derived CAR T-cell Product Platform The Company also highlighted the scientific progress of its proprietary iPSC-derived CAR T-cell product platform at the ASH Annual Meeting. In an oral presentation entitled “ Off-the-shelf Product Candidate Incorporates Novel Sword & Shield Technology Designed to Promote Functional Persistence without Conditioning Chemotherapy ”, the Company compared its novel Sword & Shield technology, which utilizes a 4-1BB-targeted CAR (ADR) alongside the complete knock-out of CD58 (CD58KO) to both target and evade host alloreactive immune cells, to other host immune evasion strategies. In preclinical studies of allogeneic models, the Company showed that its Sword and Shield Technology specifically engaged with alloreactive T cells and supported functional persistence while avoiding the killing of general host T cells and activated anti-tumor T cells. This unique observation was not seen with other approaches that are either too broad and undesirably eliminate most of the host immune system or have limited coverage and cannot adequately protect the allogeneic cell product. In a second presentation entitled “ Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells ”, the Company conducted a series of high-resolution analyses to show stimulated iPSC-derived T cells elicit primary T-cell like activation, proliferation, transcriptional and functional program engagement, and iPSC-derived CAR T cells uniquely emulate antigen-mediated response similar to primary-derived autologous CAR T cells. About Fate Therapeutics’ iPSC Product Platform Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s proprietary iPSC product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be combined and administered with other therapies, and can potentially reach a broad patient population. As a result, the Company’s platform is uniquely designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications. About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com . Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the safety and therapeutic potential of the Company’s iPSC-derived CAR T-cell product candidates, including FT819, the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the Company’s progress, plans and timelines for the clinical investigation of its product candidates, including the expected clinical development plans for FT819, the initiation and continuation of enrollment in the Company’s clinical trials, the initiation of additional clinical trials and additional dose cohorts in ongoing clinical trials of the Company’s product candidates, the timing and availability of data from the Company’s clinical trials, the therapeutic and market potential of the Company’s research and development programs and product candidates, the Company’s clinical and product development strategy, and the Company’s expectations regarding progress, plans, and timelines. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company’s research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company’s product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company’s product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company’s ongoing and planned clinical trials, difficulties or delays in manufacturing or supplying the Company’s product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. Contact: Christina Tartaglia Precision AQ 212.362.1200 christina.tartaglia@precisionaq.com